Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
NanotechnologyDrug Delivery System

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1389815

Cover Image

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1389815

Injectable Nanomedicines Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

PUBLISHED:
PAGES: 173 Pages
DELIVERY TIME: 2-5 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PPT Slides/PDF & Excel (Enterprise License)
USD 4995

Add to Cart

Description

Table of Contents

The global demand for injectable nanomedicines is witnessing significant growth, driven by advancements in nanotechnology that enhance drug safety and efficacy. These nanomedicines are designed to release drugs at targeted sites, allowing for the accumulation of drugs at the site of action, thereby minimizing side effects and improving therapeutic outcomes. Active targeting using ligands further enhances their efficacy, leading to better disease management.

Technological Advancements in Liposomal Drug Delivery Systems

One key development in this field is the use of liposomal technologies, which are employed by leading drug manufacturers for extended-release drug delivery, resulting in reduced dosages and improved patient adherence. Technologies such as DepoFoam™ and Non-PEGylated Technology (NPL) are helping reduce side effects and enhance treatment effectiveness. The adoption of complex technologies to develop unique drugs to sustain competition is expected to drive the growth of the injectable nanomedicines market.

Academic-Pharmaceutical Collaboration Drives Innovation

Collaboration between academia and the pharmaceutical industry has emerged as a driving force for innovation in the development of injectable nanomedicines. The synergy between scientific and technological expertise from academia and the resources of pharmaceutical companies has accelerated drug development, contributing to the rapid market expansion.

Challenges in Sterile Manufacturing Facilities

A limitation facing the market is the scarcity of cGMP certified facilities for manufacturing complex injectable nanomedicines. Sterile manufacturing is a critical quality attribute, and any non-conformity in procedures can result in microbial contamination and severe adverse drug reactions. Establishing suitable sterile manufacturing facilities is crucial for the production of safe injectable nanomedicines.

Increasing Government Funding for Nanomedicine Development

Governments worldwide are increasing funding for nanomedicine development, attracting commercialization interests from drug makers and intensifying market competition. The U.S. Federal Authorities, for instance, have allocated $1.4 billion under the National Nanotechnology Initiative to support nanomedicine research. The growing use of nanomedicines in drug discovery is expected to drive revenue growth in the global injectable nanomedicines market.

Segmentation

The report provides an extensive categorization of the injectable nanomedicines market, taking into account various factors such as drug type, application, end-user, and geographical region. Regarding drug type, the global injectable nanomedicines market is divided into liposomes, micelles, nanocrystals, polymeric nanoparticles, metallic nanoparticles, Mesoporous silica nanoparticles, and other variants.

In terms of applications, the global injectable nanomedicines market is categorized into cancer, central nervous system diseases, cardiovascular diseases, infection control, inflammatory diseases, and other relevant applications. When it comes to end-users, the global injectable nanomedicines market encompasses hospitals, ambulatory surgical centers, clinics, specialized drug research and development institutes, and managed care organizations.

From a geographical perspective, the injectable nanomedicines market is segmented into North America, Latin America, Europe, Asia Pacific, and the Middle East & Africa (MEA).

Competitive Landscape

Key players in the injectable nanomedicines market include: Merck KGaA, Amgen Inc., Pfizer Inc., Lupin, Janssen Biotech Inc., Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Pacira Pharmaceuticals Inc., Celgene Corporation, and Bausch & Lomb Incorporated. These companies offer a wide range of injectable nanomedicines. Emerging players are focusing on innovative R&D efforts to expand their product portfolios, with several injectable nanomedicines currently undergoing clinical trials and expected to launch in the near future, intensifying market competition.

Show more

Table of Contents

1. Executive Summary

  • 1.1. Global Injectable Nanomedicines Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Injectable Nanomedicines Market Outlook, 2018 - 2031

  • 3.1. Global Injectable Nanomedicines Market Outlook, by Drug, Value (US$ Bn), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. Liposomes
      • 3.1.1.2. Micelles
      • 3.1.1.3. Nanocrystals
      • 3.1.1.4. Polymeric Nanoparticles
      • 3.1.1.5. Metallic Nanoparticles
      • 3.1.1.6. Mesoporous Silica Nanoparticles
      • 3.1.1.7. Others
  • 3.2. Global Injectable Nanomedicines Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Cancers
      • 3.2.1.2. Central Nervous System Diseases
      • 3.2.1.3. Cardiovascular diseases
      • 3.2.1.4. Infection Control
      • 3.2.1.5. Inflammatory Diseases
      • 3.2.1.6. Others
  • 3.3. Global Injectable Nanomedicines Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. Hospitals
      • 3.3.1.2. Ambulatory Surgical Centers
      • 3.3.1.3. Clinics
      • 3.3.1.4. Specialized Drugs R&D Institutes
      • 3.3.1.5. Managed Care Organizations
  • 3.4. Global Injectable Nanomedicines Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
    • 3.4.1. Key Highlights
      • 3.4.1.1. North America
      • 3.4.1.2. Europe
      • 3.4.1.3. Asia Pacific
      • 3.4.1.4. Latin America
      • 3.4.1.5. Middle East & Africa

4. North America Injectable Nanomedicines Market Outlook, 2018 - 2031

  • 4.1. North America Injectable Nanomedicines Market Outlook, by Drug, Value (US$ Bn), 2018 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. Liposomes
      • 4.1.1.2. Micelles
      • 4.1.1.3. Nanocrystals
      • 4.1.1.4. Polymeric Nanoparticles
      • 4.1.1.5. Metallic Nanoparticles
      • 4.1.1.6. Mesoporous Silica Nanoparticles
      • 4.1.1.7. Others
  • 4.2. North America Injectable Nanomedicines Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Cancers
      • 4.2.1.2. Central Nervous System Diseases
      • 4.2.1.3. Cardiovascular diseases
      • 4.2.1.4. Infection Control
      • 4.2.1.5. Inflammatory Diseases
      • 4.2.1.6. Others
  • 4.3. North America Injectable Nanomedicines Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. Hospitals
      • 4.3.1.2. Ambulatory Surgical Centers
      • 4.3.1.3. Clinics
      • 4.3.1.4. Specialized Drugs R&D Institutes
      • 4.3.1.5. Managed Care Organizations
    • 4.3.2. BPS Analysis/Market Attractiveness Analysis
  • 4.4. North America Injectable Nanomedicines Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 4.4.1. Key Highlights
      • 4.4.1.1. U.S. Injectable Nanomedicines Market by Drug, Value (US$ Bn), 2018 - 2031
      • 4.4.1.2. U.S. Injectable Nanomedicines Market by Application, Value (US$ Bn), 2018 - 2031
      • 4.4.1.3. U.S. Injectable Nanomedicines Market by End User, Value (US$ Bn), 2018 - 2031
      • 4.4.1.4. Canada Injectable Nanomedicines Market by Drug, Value (US$ Bn), 2018 - 2031
      • 4.4.1.5. Canada Injectable Nanomedicines Market by Application, Value (US$ Bn), 2018 - 2031
      • 4.4.1.6. Canada Injectable Nanomedicines Market by End User, Value (US$ Bn), 2018 - 2031
    • 4.4.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Injectable Nanomedicines Market Outlook, 2018 - 2031

  • 5.1. Europe Injectable Nanomedicines Market Outlook, by Drug, Value (US$ Bn), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Liposomes
      • 5.1.1.2. Micelles
      • 5.1.1.3. Nanocrystals
      • 5.1.1.4. Polymeric Nanoparticles
      • 5.1.1.5. Metallic Nanoparticles
      • 5.1.1.6. Mesoporous Silica Nanoparticles
      • 5.1.1.7. Others
  • 5.2. Europe Injectable Nanomedicines Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Cancers
      • 5.2.1.2. Central Nervous System Diseases
      • 5.2.1.3. Cardiovascular diseases
      • 5.2.1.4. Infection Control
      • 5.2.1.5. Inflammatory Diseases
      • 5.2.1.6. Others
  • 5.3. Europe Injectable Nanomedicines Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Hospitals
      • 5.3.1.2. Ambulatory Surgical Centers
      • 5.3.1.3. Clinics
      • 5.3.1.4. Specialized Drugs R&D Institutes
      • 5.3.1.5. Managed Care Organizations
    • 5.3.2. BPS Analysis/Market Attractiveness Analysis
  • 5.4. Europe Injectable Nanomedicines Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 5.4.1. Key Highlights
      • 5.4.1.1. Germany Injectable Nanomedicines Market by Drug, Value (US$ Bn), 2018 - 2031
      • 5.4.1.2. Germany Injectable Nanomedicines Market by Application, Value (US$ Bn), 2018 - 2031
      • 5.4.1.3. Germany Injectable Nanomedicines Market by End User, Value (US$ Bn), 2018 - 2031
      • 5.4.1.4. U.K. Injectable Nanomedicines Market by Drug, Value (US$ Bn), 2018 - 2031
      • 5.4.1.5. U.K. Injectable Nanomedicines Market by Application, Value (US$ Bn), 2018 - 2031
      • 5.4.1.6. U.K. Injectable Nanomedicines Market by End User, Value (US$ Bn), 2018 - 2031
      • 5.4.1.7. France Injectable Nanomedicines Market by Drug, Value (US$ Bn), 2018 - 2031
      • 5.4.1.8. France Injectable Nanomedicines Market by Application, Value (US$ Bn), 2018 - 2031
      • 5.4.1.9. France Injectable Nanomedicines Market by End User, Value (US$ Bn), 2018 - 2031
      • 5.4.1.10. Italy Injectable Nanomedicines Market by Drug, Value (US$ Bn), 2018 - 2031
      • 5.4.1.11. Italy Injectable Nanomedicines Market by Application, Value (US$ Bn), 2018 - 2031
      • 5.4.1.12. Italy Injectable Nanomedicines Market by End User, Value (US$ Bn), 2018 - 2031
      • 5.4.1.13. Turkey Injectable Nanomedicines Market by Drug, Value (US$ Bn), 2018 - 2031
      • 5.4.1.14. Turkey Injectable Nanomedicines Market by Application, Value (US$ Bn), 2018 - 2031
      • 5.4.1.15. Turkey Injectable Nanomedicines Market by End User, Value (US$ Bn), 2018 - 2031
      • 5.4.1.16. Russia Injectable Nanomedicines Market by Drug, Value (US$ Bn), 2018 - 2031
      • 5.4.1.17. Russia Injectable Nanomedicines Market by Application, Value (US$ Bn), 2018 - 2031
      • 5.4.1.18. Russia Injectable Nanomedicines Market by End User, Value (US$ Bn), 2018 - 2031
      • 5.4.1.19. Rest of Europe Injectable Nanomedicines Market by Drug, Value (US$ Bn), 2018 - 2031
      • 5.4.1.20. Rest of Europe Injectable Nanomedicines Market by Application, Value (US$ Bn), 2018 - 2031
      • 5.4.1.21. Rest of Europe Injectable Nanomedicines Market by End User, Value (US$ Bn), 2018 - 2031
    • 5.4.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Injectable Nanomedicines Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Injectable Nanomedicines Market Outlook, by Drug, Value (US$ Bn), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Liposomes
      • 6.1.1.2. Micelles
      • 6.1.1.3. Nanocrystals
      • 6.1.1.4. Polymeric Nanoparticles
      • 6.1.1.5. Metallic Nanoparticles
      • 6.1.1.6. Mesoporous Silica Nanoparticles
      • 6.1.1.7. Others
  • 6.2. Asia Pacific Injectable Nanomedicines Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Cancers
      • 6.2.1.2. Central Nervous System Diseases
      • 6.2.1.3. Cardiovascular diseases
      • 6.2.1.4. Infection Control
      • 6.2.1.5. Inflammatory Diseases
      • 6.2.1.6. Others
  • 6.3. Asia Pacific Injectable Nanomedicines Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. Hospitals
      • 6.3.1.2. Ambulatory Surgical Centers
      • 6.3.1.3. Clinics
      • 6.3.1.4. Specialized Drugs R&D Institutes
      • 6.3.1.5. Managed Care Organizations
    • 6.3.2. BPS Analysis/Market Attractiveness Analysis
  • 6.4. Asia Pacific Injectable Nanomedicines Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 6.4.1. Key Highlights
      • 6.4.1.1. China Injectable Nanomedicines Market by Drug, Value (US$ Bn), 2018 - 2031
      • 6.4.1.2. China Injectable Nanomedicines Market by Application, Value (US$ Bn), 2018 - 2031
      • 6.4.1.3. China Injectable Nanomedicines Market by End User, Value (US$ Bn), 2018 - 2031
      • 6.4.1.4. Japan Injectable Nanomedicines Market by Drug, Value (US$ Bn), 2018 - 2031
      • 6.4.1.5. Japan Injectable Nanomedicines Market by Application, Value (US$ Bn), 2018 - 2031
      • 6.4.1.6. Japan Injectable Nanomedicines Market by End User, Value (US$ Bn), 2018 - 2031
      • 6.4.1.7. South Korea Injectable Nanomedicines Market by Drug, Value (US$ Bn), 2018 - 2031
      • 6.4.1.8. South Korea Injectable Nanomedicines Market by Application, Value (US$ Bn), 2018 - 2031
      • 6.4.1.9. South Korea Injectable Nanomedicines Market by End User, Value (US$ Bn), 2018 - 2031
      • 6.4.1.10. India Injectable Nanomedicines Market by Drug, Value (US$ Bn), 2018 - 2031
      • 6.4.1.11. India Injectable Nanomedicines Market by Application, Value (US$ Bn), 2018 - 2031
      • 6.4.1.12. India Injectable Nanomedicines Market by End User, Value (US$ Bn), 2018 - 2031
      • 6.4.1.13. Southeast Asia Injectable Nanomedicines Market by Drug, Value (US$ Bn), 2018 - 2031
      • 6.4.1.14. Southeast Asia Injectable Nanomedicines Market by Application, Value (US$ Bn), 2018 - 2031
      • 6.4.1.15. Southeast Asia Injectable Nanomedicines Market by End User, Value (US$ Bn), 2018 - 2031
      • 6.4.1.16. Rest of Asia Pacific Injectable Nanomedicines Market by Drug, Value (US$ Bn), 2018 - 2031
      • 6.4.1.17. Rest of Asia Pacific Injectable Nanomedicines Market by Application, Value (US$ Bn), 2018 - 2031
      • 6.4.1.18. Rest of Asia Pacific Injectable Nanomedicines Market by End User, Value (US$ Bn), 2018 - 2031
    • 6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Injectable Nanomedicines Market Outlook, 2018 - 2031

  • 7.1. Latin America Injectable Nanomedicines Market Outlook, by Drug, Value (US$ Bn), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Liposomes
      • 7.1.1.2. Micelles
      • 7.1.1.3. Nanocrystals
      • 7.1.1.4. Polymeric Nanoparticles
      • 7.1.1.5. Metallic Nanoparticles
      • 7.1.1.6. Mesoporous Silica Nanoparticles
      • 7.1.1.7. Others
  • 7.2. Latin America Injectable Nanomedicines Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
      • 7.2.1.1. Cancers
      • 7.2.1.2. Central Nervous System Diseases
      • 7.2.1.3. Cardiovascular diseases
      • 7.2.1.4. Infection Control
      • 7.2.1.5. Inflammatory Diseases
      • 7.2.1.6. Others
  • 7.3. Latin America Injectable Nanomedicines Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Hospitals
      • 7.3.1.2. Ambulatory Surgical Centers
      • 7.3.1.3. Clinics
      • 7.3.1.4. Specialized Drugs R&D Institutes
      • 7.3.1.5. Managed Care Organizations
    • 7.3.2. BPS Analysis/Market Attractiveness Analysis
  • 7.4. Latin America Injectable Nanomedicines Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 7.4.1. Key Highlights
      • 7.4.1.1. Brazil Injectable Nanomedicines Market by Drug, Value (US$ Bn), 2018 - 2031
      • 7.4.1.2. Brazil Injectable Nanomedicines Market by Application, Value (US$ Bn), 2018 - 2031
      • 7.4.1.3. Brazil Injectable Nanomedicines Market by End User, Value (US$ Bn), 2018 - 2031
      • 7.4.1.4. Mexico Injectable Nanomedicines Market by Drug, Value (US$ Bn), 2018 - 2031
      • 7.4.1.5. Mexico Injectable Nanomedicines Market by Application, Value (US$ Bn), 2018 - 2031
      • 7.4.1.6. Mexico Injectable Nanomedicines Market by End User, Value (US$ Bn), 2018 - 2031
      • 7.4.1.7. Argentina Injectable Nanomedicines Market by Drug, Value (US$ Bn), 2018 - 2031
      • 7.4.1.8. Argentina Injectable Nanomedicines Market by Application, Value (US$ Bn), 2018 - 2031
      • 7.4.1.9. Argentina Injectable Nanomedicines Market by End User, Value (US$ Bn), 2018 - 2031
      • 7.4.1.10. Rest of Latin America Injectable Nanomedicines Market by Drug, Value (US$ Bn), 2018 - 2031
      • 7.4.1.11. Rest of Latin America Injectable Nanomedicines Market by Application, Value (US$ Bn), 2018 - 2031
      • 7.4.1.12. Rest of Latin America Injectable Nanomedicines Market by End User, Value (US$ Bn), 2018 - 2031
    • 7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Injectable Nanomedicines Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Injectable Nanomedicines Market Outlook, by Drug, Value (US$ Bn), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Liposomes
      • 8.1.1.2. Micelles
      • 8.1.1.3. Nanocrystals
      • 8.1.1.4. Polymeric Nanoparticles
      • 8.1.1.5. Metallic Nanoparticles
      • 8.1.1.6. Mesoporous Silica Nanoparticles
      • 8.1.1.7. Others
  • 8.2. Middle East & Africa Injectable Nanomedicines Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Cancers
      • 8.2.1.2. Central Nervous System Diseases
      • 8.2.1.3. Cardiovascular diseases
      • 8.2.1.4. Infection Control
      • 8.2.1.5. Inflammatory Diseases
      • 8.2.1.6. Others
  • 8.3. Middle East & Africa Injectable Nanomedicines Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. Hospitals
      • 8.3.1.2. Ambulatory Surgical Centers
      • 8.3.1.3. Clinics
      • 8.3.1.4. Specialized Drugs R&D Institutes
      • 8.3.1.5. Managed Care Organizations
    • 8.3.2. BPS Analysis/Market Attractiveness Analysis
  • 8.4. Middle East & Africa Injectable Nanomedicines Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 8.4.1. Key Highlights
      • 8.4.1.1. GCC Injectable Nanomedicines Market by Drug, Value (US$ Bn), 2018 - 2031
      • 8.4.1.2. GCC Injectable Nanomedicines Market by Application, Value (US$ Bn), 2018 - 2031
      • 8.4.1.3. GCC Injectable Nanomedicines Market by End User, Value (US$ Bn), 2018 - 2031
      • 8.4.1.4. South Africa Injectable Nanomedicines Market by Drug, Value (US$ Bn), 2018 - 2031
      • 8.4.1.5. South Africa Injectable Nanomedicines Market by Application, Value (US$ Bn), 2018 - 2031
      • 8.4.1.6. South Africa Injectable Nanomedicines Market by End User, Value (US$ Bn), 2018 - 2031
      • 8.4.1.7. Egypt Injectable Nanomedicines Market by Drug, Value (US$ Bn), 2018 - 2031
      • 8.4.1.8. Egypt Injectable Nanomedicines Market by Application, Value (US$ Bn), 2018 - 2031
      • 8.4.1.9. Egypt Injectable Nanomedicines Market by End User, Value (US$ Bn), 2018 - 2031
      • 8.4.1.10. Nigeria Injectable Nanomedicines Market by Drug, Value (US$ Bn), 2018 - 2031
      • 8.4.1.11. Nigeria Injectable Nanomedicines Market by Application, Value (US$ Bn), 2018 - 2031
      • 8.4.1.12. Nigeria Injectable Nanomedicines Market by End User, Value (US$ Bn), 2018 - 2031
      • 8.4.1.13. Rest of Middle East & Africa Injectable Nanomedicines Market by Drug, Value (US$ Bn), 2018 - 2031
      • 8.4.1.14. Rest of Middle East & Africa Injectable Nanomedicines Market by Application, Value (US$ Bn), 2018 - 2031
      • 8.4.1.15. Rest of Middle East & Africa Injectable Nanomedicines Market by End User, Value (US$ Bn), 2018 - 2031
    • 8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. By End User vs by Application Heat map
  • 9.2. Manufacturer vs by Application Heatmap
  • 9.3. Company Market Share Analysis, 2023
  • 9.4. Competitive Dashboard
  • 9.5. Company Profiles
    • 9.5.1. Merck & Co., Inc.
      • 9.5.1.1. Company Overview
      • 9.5.1.2. Product Portfolio
      • 9.5.1.3. Financial Overview
      • 9.5.1.4. Business Strategies and Development
    • 9.5.2. Lupin
      • 9.5.2.1. Company Overview
      • 9.5.2.2. Product Portfolio
      • 9.5.2.3. Financial Overview
      • 9.5.2.4. Business Strategies and Development
    • 9.5.3. Pacira Pharmaceuticals Inc.
      • 9.5.3.1. Company Overview
      • 9.5.3.2. Product Portfolio
      • 9.5.3.3. Financial Overview
      • 9.5.3.4. Business Strategies and Development
    • 9.5.4. Celgene Pharmaceutical Co. Ltd.
      • 9.5.4.1. Company Overview
      • 9.5.4.2. Product Portfolio
      • 9.5.4.3. Financial Overview
      • 9.5.4.4. Business Strategies and Development
    • 9.5.5. Amgen, Inc.
      • 9.5.5.1. Company Overview
      • 9.5.5.2. Product Portfolio
      • 9.5.5.3. Financial Overview
      • 9.5.5.4. Business Strategies and Development
    • 9.5.6. Janssen Biotech Inc. (Sub. Johnson & Johnson Services, Inc.)
      • 9.5.6.1. Company Overview
      • 9.5.6.2. Product Portfolio
      • 9.5.6.3. Financial Overview
      • 9.5.6.4. Business Strategies and Development
    • 9.5.7. Pfizer Inc.
      • 9.5.7.1. Company Overview
      • 9.5.7.2. Product Portfolio
      • 9.5.7.3. Financial Overview
      • 9.5.7.4. Business Strategies and Development
    • 9.5.8. Hoffmann-La Roche Ltd.
      • 9.5.8.1. Company Overview
      • 9.5.8.2. Product Portfolio
      • 9.5.8.3. Financial Overview
      • 9.5.8.4. Business Strategies and Development
    • 9.5.9. Teva Pharmaceutical Industries Ltd.
      • 9.5.9.1. Company Overview
      • 9.5.9.2. Product Portfolio
      • 9.5.9.3. Financial Overview
      • 9.5.9.4. Business Strategies and Development
    • 9.5.10. Bausch & Lomb Incorporated.
      • 9.5.10.1. Company Overview
      • 9.5.10.2. Product Portfolio
      • 9.5.10.3. Financial Overview
      • 9.5.10.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!